Skip to content

Experience with Atosiban

Our initial experience with Atosiban for preterm labour in a tertiary care centre

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/01/017054
Enrollment
100
Registered
2019-01-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O600- Preterm labor without delivery

Interventions

Intervention1: Atosiban 7.5 mg/ml: Atosiban as intravenous (i.v.) infusion for 48 hours in three successive stages. The treatment will be initiated by an initial bolus dose (6.75 mg) administered over

Sponsors

Army Research and Referral Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients with preterm labour Singleton/ multi fetal gestation beyond 24weeks of gestation to 33 weeks + 6 days with intact amniotic membranes

Exclusion criteria

Exclusion criteria: 1. All patients with preterm rupture of membranes 2. All patients of abruptio placenta 3. All patients less than 24 weeks of gestation 4. All patients more than 34 weeks of gestation 5. All patients with fever , tachycardia and positive CRP in maternal blood on admission 6. All patients with IUD /congenital anomaly 7. Patients needing more than one tocolytic agent.

Design outcomes

Primary

MeasureTime frame
Proportion of patients who will be undelivered upto 72 hours after completion of treatment phase and those not delivered till the end of 7 daysTimepoint: Throughout study duration

Secondary

MeasureTime frame
1.Perinatal death. 2.Mode of delivery. 3.Emergency caesarean (if any) Timepoint: At the time of delivery

Countries

India

Contacts

Public ContactCol Dr Reema Kumar Bhatt

Army Research and Referral Hospital

reemakamalbhatt@yahoo.co.in9205646811

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026